Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer

Current Cancer Drug Targets

Volumn 7, Issue 2, 2007, Pages 169-174

  Nakao, A ^a   Takeda, S ^a   Shimoyama, S ^a   Kasuya, H ^a   Kimata, H ^a   Teshigahara, O ^a   Sawaki, M ^a   Kikumori, T ^a   Kodera, Y ^a   Nagasaka, T ^a   Goshima, F ^a   Nishiyama, Y ^a   Imai, T ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; Clinical experiment; Herpes virus therapy; HF10; Oncolytic viral therapy; Pancreatic cancer

Indexed keywords

HF 10; ONCOLYTIC HERPES VIRUS; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; BODY TEMPERATURE; BREAST CANCER; CANCER GRADING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; ISOGRAFT; MALE; PANCREAS CANCER; REVIEW; SIDE EFFECT; SKIN REDNESS; TUMOR CELL; VIROLOGY; VIRUS INFECTION;

AGED; ANIMALS; BREAST NEOPLASMS; FEMALE; HERPESVIRUS 1, HUMAN; HUMANS; MALE; MIDDLE AGED; MUTATION; ONCOLYTIC VIROTHERAPY; PANCREATIC NEOPLASMS; RESEARCH DESIGN; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 33847390326     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800907780058808     Document Type: Review

References (20)

1. Nishiyama, Y.; Kimura, H.; Daikoku, T. Complementary lethal invasion of the central nervous system by nonneuroinvasive herpes simplex virus type 1 and 2. J. Virol. 1990, 65, 4520-4524.
2. Yamada, Y.; Kimura, H.; Morishima, T.; Daikoku, T.; Maeno, K.; Nishiyama, Y. The pathogenicity of ribonucleotide reductase-null mutants of herpes simplex virus type 1 in mice. J. Infect. Dis. 1991, 164, 1091-1097.
3. Nishiyama, Y.; Yamada, Y.; Kurachi, R.; Daikoku, T. Construction of a US3 lacZ insertion mutant of herpes simplex virus type 2 and characterization of its phenotype in vitro and in vivo. Virology 1992, 190, 256-268.
4. Takakuwa, H.; Goshima, F.; Nozawa, N.; Yoshikawa, T.; Kimata, H.; Nakao, A.; Nawa, A.; Kurata, T.; Sata, T.; Nishiyama, Y. Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. Arch. Virol. 2003, 148, 813-825.
5. Kimata, H.; Takakuwa, H.; Goshima, F.; Teshigahara, O.; Nakao, A.; Kurata, T.; Sata, T.; Nishiyama, Y. Effective treatment of disseminated peritoneal colon cancer with new replication-component herpes simplex viruses. Hepato-Gastroenterol. 2003, 50, 961-966.
6. Teshigahara, O.; Goshima, F.; Takao, K.; Kohno, S.; Kimata, H.; Nakao, A.; Nishiyama, Y. Oncolytic viral therapy for breast cancer with Herpes Simplex Virus Type 1 mutant HF10. J. Surg. Oncol. 2004, 85, 42-47.
7. Kohno, S.; Luo, C.; Goshima, F.; Nishiyama, Y.; Sata, T.; Ono, Y. Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer. Urology 2005, 66, 1116-1121.
8. Nakao, A.; Kimata, H.; Imai, T.; Kikumori, T.; Teshigahara, O.; Nagasaka, T.; Goshima, F.; Nishiyama, Y. Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer. Ann. Oncol. 2004, 15, 987-991.
9. Kimata, H.; Imai, T.; Kikumori, T.; Teshigahara, O.; Nagasaka, T.; Goshima, F.; Nishiyama, Y.; Nakao, A. Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer. Ann. Surg. Oncol. 2006, 13, 1078-1084.
10. Becker, Y.; Hadar, J.; Tabor, E.; Ben-Hur, T.; Raibstein, I.; Rösen, A.; Darai, G. A sequence in Hpal-P fragment of herpes simplex virus-1 DNA determines intraperitoneal virulence in mice. Virology 1986, 149, 255-259.
11. Berkowitz, C.; Moyal, M.; Rösen-Wolff, A.; Darai, G.; Becker, Y. Herpes simplex virus type 1 (HSV-1) UL56 gene is involved in viral intraperitoneal pathogenicity to immunocompetent mice. Arch. Virol. 1994, 134, 73-83.
12. Koshizuka, T.; Goshima, F.; Takakuwa, H.; Nozawa, N.; Daikoku, T.; Koiwai, O.; Nishiyama, Y. Identification and characterization of the UL56 gene product of herpes simplex virus type 2. J. Virol. 2002, 76, 6718-6728.
13. Committee for Production of Histopathological Criteria, Japanese Breast Cancer Society. Histopathological criteria for assessment of therapeutic response in breast cancer. Breast Cancer 2001, 8, 1-7.
14. Culver, K. W.; Ram, Z.; Wallbridge, S.; Ishii, H.; Oldfield, E. H.; Blaese, R. M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992, 256, 1550-1552.
15. Qazilbash, M. H.; Xiao, X.; Seth, P.; Cowan, K. H.; Walsh, C. E. Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53. Gene Ther. 1997, 4, 675-682.
16. Martuza, R. L.; Malick, A.; Markert, J. M.; Ruffner, K. L.; Coen, D. M. Experimental therapy in human glioma by means of a genetically engineered virus mutant. Science 1991, 252, 854-856.
17. Goldstein, D. J.; Weller, S. K. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 1988, 166, 41-51.
18. Wong, R. J.; Kim, S. H.; Joe, J. K.; Shah, J. P.; Johnson, P. A.; Fong, Y. M. Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J. Am. Coll. Surg. 2001, 193, 12-21.
19. Cozzi, P. J.; Malhotra, S.; McAuliffe, P.; Kooby, D. A.; Federoff, H. J.; Huryk, B.; Johnson, P.; Scardino, P. T.; Heston, W. D. W.; Fong, Y. Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. FASEB J. 2001, 15, 1306-1308.
20. Meignier, B.; Martin, B.; Whitley, R. J.; Roizman, B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J. Infect. Dis. 1990, 2, 313-221.